Literature DB >> 28938461

Adipokines and Their Receptors Are Widely Expressed and Distinctly Regulated by the Metabolic Environment in the Prostate of Male Mice: Direct Role Under Normal and Tumoral Conditions.

André Sarmento-Cabral1,2,3,4,5, Fernando L-López1,2,3,4,5, Raúl M Luque1,2,3,4,5.   

Abstract

Adipose tissue-derived adipokines (i.e., leptin/adiponectin/resistin) play important roles in the regulation of several pathophysiologic processes through the activation of specific receptors. However, although adipokines and their receptors are widely distributed in many tissues and exhibit a clear modulation according to particular metabolic conditions (e.g., obesity and/or fasting), their expression, regulation, and putative action on normal prostate glands (PGs; a hormone-dependent organ tightly regulated by the endocrine-metabolic milieu) are still to be defined. Different in vivo/in vitro models were used to comprehensively characterize the expression pattern and actions of different adipokine systems (i.e., leptin/adiponectin/resistin/receptors) in mouse PGs. Adiponectin, resistin, and adiponectin receptors (1 and 2) and leptin receptor are coexpressed at different levels in PG cells, wherein they are finely regulated under fasting and/or obesity conditions. Furthermore, treatment with different adipokines exerted both homologous and heterologous regulation of specific adipokines/receptor-synthesis and altered the expression of key proliferation and oncogenesis markers (i.e., Ki67/c-Myc/p53) in mouse PG cell cultures, wherein some of these actions might be elicited through extracellular signal-regulated kinase (ERK) activation. Moreover, treatment with leptin, adiponectin, and resistin differentially regulated key functional parameters [i.e., proliferation and migration capacity and/or prostate-specific antigen (PSA) secretion] in human normal and/or tumoral prostate cell lines. Altogether, our data show that various adipokine and receptor systems are differentially expressed in normal PG cells; that their expression is under a complex ligand- and receptor-selective regulation under extreme metabolic conditions; and that they mediate distinctive and common direct actions in normal and tumoral PG cells (i.e., homologous and heterologous regulation of ligand and receptor synthesis, ERK signaling activation, modulation of proliferation markers, proliferation and migration capacity, and PSA secretion), suggesting a relevant role of these systems in the regulation of PG pathophysiology.
Copyright © 2017 Endocrine Society.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28938461     DOI: 10.1210/en.2017-00370

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  4 in total

1.  Seminal Levels of Omentin-1/ITLN1 in Inflammatory Conditions Related to Male Infertility and Localization in Spermatozoa and Tissues of Male Reproductive System.

Authors:  Elena Moretti; Cinzia Signorini; Daria Noto; Sergio Antonio Tripodi; Andrea Menchiari; Ester Sorrentino; Giulia Collodel
Journal:  J Inflamm Res       Date:  2022-03-26

Review 2.  Thromboinflammatory Processes at the Nexus of Metabolic Dysfunction and Prostate Cancer: The Emerging Role of Periprostatic Adipose Tissue.

Authors:  Ibrahim AlZaim; Aya Al-Saidi; Safaa H Hammoud; Nadine Darwiche; Yusra Al-Dhaheri; Ali H Eid; Ahmed F El-Yazbi
Journal:  Cancers (Basel)       Date:  2022-03-25       Impact factor: 6.639

Review 3.  Bone Marrow Adipocyte: An Intimate Partner With Tumor Cells in Bone Metastasis.

Authors:  Guojing Luo; Yuedong He; Xijie Yu
Journal:  Front Endocrinol (Lausanne)       Date:  2018-06-22       Impact factor: 5.555

4.  Clinical association of metabolic syndrome, C-reactive protein and testosterone levels with clinically significant prostate cancer.

Authors:  Enrique Gómez-Gómez; Julia Carrasco-Valiente; Juan Pablo Campos-Hernández; Ana Maria Blanca-Pedregosa; Juan Manuel Jiménez-Vacas; Jesus Ruiz-García; Jose Valero-Rosa; Raul Miguel Luque; María José Requena-Tapia
Journal:  J Cell Mol Med       Date:  2018-11-18       Impact factor: 5.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.